Sign In | Join Free | My himfr.com |
|
Ask Lasest Price | |
Brand Name : | complex |
Model Number : | BGH-218 |
Certification : | ISO9001/Halal/Kosher |
Price : | US$825-830/kg |
Payment Terms : | L/C, D/A, D/P, T/T, Western Union, MoneyGram |
Supply Ability : | 5000000kg per year |
Delivery Time : | 3 workdays after payment |
health care product nutrition supplement breviscapine with best
price
product details
Product name:Erigeron breviscapus Extract
Extract source:Bergenia purpurascens.
Specification:98%
Active ingredient:Breviscapine
Used Part:flower
CAS NO. : 116122-36-2
Molecular formula :C21H18O12
Molecular weight:462.4
Appearance:light yellow Powder
Flavor: Characteristic taste
Particle Size:80% pass through 80 mesh sieve
Test mothed: HPLC
Extract Solvent: Ethanol & Water
Solubility: Soluble in water, ethanol
Usage: Pharmaceuticals, healthcares,and cosmetics
Product Description
Breviscapine is a mixture of
flavonoid
glycosides extracted from the Chinese herbs. Previous studies have shown that
breviscapine possesses comprehensive pharmacological functions.
However, very little is known about whether breviscapine have
protective role on cardiac hypertrophy. The aim of the present
study was to determine whether breviscapine attenuates cardiac
hypertrophy induced by
angiotensin II (Ang
II) in cultured neonatal
rat cardiac myocytes in vitro and pressure-overload-induced cardiac
hypertrophy in
mice in vivo. Our data demonstrated that breviscapine (2.5-15 microM)
dose-dependently blocked cardiac hypertrophy induced by
Ang II (1 microM) in vitro. The results further revealed that
breviscapine (50 mg/kg/day) prevented cardiac hypertrophy induced
by aortic banding as assessed by heart weight/body weight and lung
weight/body weight ratios, echocardiographic parameters, and gene
expression of hypertrophic markers. The inhibitory effect of
breviscapine on cardiac hypertrophy is mediated by disrupting
PKC-alpha-dependent
ERK1/2 and
PI3K/AKT signaling. Further studies showed that breviscapine inhibited
inflammation by blocking NF-kappaB signaling, and attenuated
fibrosis and
collagen synthesis through abrogating
Smad2/3 signaling. Therefore, these findings indicate that breviscapine,
which is a potentially safe and inexpensive therapy for clinical
use, has protective potential in targeting cardiac hypertrophy and
fibrosis through suppression of
PKC-alpha-dependent signaling.
Product Analysis
Item | Specification | Result | Method |
BasicProduct Information | |||
Product name | breviscapine | ||
Part of the Plant | flower | Conform | / |
Country of Origin | China | Conform | / |
Organoleptic Data | |||
Appearance | Fine powder | Conform | NLS-QCS-1008 |
Color | Light yellow powder | Conform | GB/T 5492-2008 |
Odor& Taste | Characteristic | Conform | GB/T 5492-2008 |
Process Data | |||
Solvent(s) Used | Water and ethyl alcohol | Conform | / |
Extract ration | / | Conform | |
Content | Paeoniflorin≥98% | 98.18 | |
Drying Method | Spray drying | Conform | / |
Excipient | Maltodextrin | Conform | / |
Physical Characteristics | |||
Particle Size (80 mesh) | 98.0%pass 80mesh | Conform | GB/T 5507-2008 |
Moisture | <5.0% | 2.8% | GB/T 14769-1993 |
Ash Content | <4.0% | 1.4% | AOAC 942.05, 18th |
Solvent Residue | Eur. Pharm | Conform | NLS-QCS-1007 |
Heavy Metals | |||
Total Heavy Metals | <10 ppm | Conform | USP <231>, method II |
Arsenic | <1.0 ppm | Conform | AOAC 986.15, 18th |
Lead | <1.0 ppm | Conform | AOAC 986.15, 18th |
Mercury | <0.5 ppm | Conform | AOAC 971.21, 18th |
Pesticide Residue | |||
666 | <0.2ppm | Conform | GB/T5009.19-1996 |
DDT | <0.2ppm | Conform | GB/T5009.19-1996 |
Microbiology | |||
Total Plate Count | <1,000cfu/g | 17cfu/g | AOAC 990.12, 18th |
Total Yeast & Mold | <100cfu/g | 3cfu/g | FDA (BAM) Chapter 18, 8th Ed. |
E. Coli | Negative | Negative | AOAC 997.11, 18th |
Salmonella | Negative | Negative | FDA (BAM) Chapter 5, 8th Ed. |
Product Function
Pharmacological effects:
1, to improve cerebral blood circulation, increase cerebral blood
flow, reducing vascular resistance, increase the permeability of
the blood-brain barrier, conducive to the prevention and treatment
of cerebral thrombosis formation.
2, the expansion of the coronary artery and peripheral vascular,
reducing myocardial oxygen consumption, to increase nutrition
myocardial blood flow, improve myocardial microcirculation.
3, lower cholesterol, reduce high blood viscosity, platelet
aggregation.
4, increasing the phagocytic function of the liver
reticuloendothelial cells and macrophages, increased blood CAMP
content, improve the immune system.
5, inhibition of intravascular coagulation, fibrinolysis promoting,
reducing fibrinogen, and anti-tied thrombolysis.
Functions and Indications:
The blood stasis Tongluozhitong. Suitable for hemiplegia, cerebral
infarction, cerebral thrombus formation, sequelae of stroke,
coronary heart disease, angina, ischemic heart disease, Alzheimer's
the hyperviscosity, dizziness psychosis.
![]() |